pneumonia
infect
lung
tissu
consid
forgotten
killer
world
health
organ
place
lower
respiratori
infect
third
common
caus
death
planet
respons
approxim
million
death
yearli
usa
pneumonia
influenza
caus
approxim
death
ninth
lead
caus
death
total
communityacquir
pneumonia
cap
patient
requir
hospit
mainli
due
sever
diseas
sever
cap
requir
critic
care
may
undergo
mechan
ventil
suffer
concomit
septic
shock
spite
avail
affect
antibiot
guidelin
rational
use
cap
high
mortal
relat
common
infect
chang
last
year
innat
acquir
pulmonari
defens
mechan
suffici
keep
lower
respiratori
tract
steril
despit
constant
exposur
particul
materi
microorgan
via
micro
aspir
develop
cap
indic
exposur
particularli
virul
microorgan
overwhelm
inoculum
microorgan
defect
host
defens
combin
factor
lung
infect
initi
immun
respons
led
neutrophil
releas
sever
granul
subtyp
abil
kill
microb
also
potenti
caus
tissu
damag
failur
control
excess
inflamm
andor
neutrophil
activ
result
exagger
lung
system
inflamm
lead
sever
diseas
immun
respons
cap
may
vari
differ
microb
may
trigger
differ
inflammatori
respons
depend
intrins
properti
clinic
outcom
cap
determin
causal
agent
interact
immun
respons
pathogen
clearanc
extrem
import
balanc
interact
regul
complex
interact
immun
cell
pro
antiinflammatori
cytokin
role
cytokin
cap
fulli
understood
current
studi
discov
affect
cap
outcom
well
known
cytokin
storm
present
sever
cap
addit
appeal
adjuv
therapi
target
regul
immun
respons
could
use
case
glucocorticoid
treatment
use
immunomodul
date
none
treatment
licens
purpos
thu
focu
review
recent
find
date
regard
system
local
cytokin
environ
possibl
implic
cap
sever
lung
infect
addit
coadjuv
therapi
analyz
review
may
repres
area
opportun
therapeut
redirect
cap
wide
variat
report
etiolog
cap
may
depend
part
diagnost
techniqu
use
popul
studi
preantibiot
era
streptococcu
pneumonia
caus
pneumonia
case
etiolog
found
new
diagnost
tool
avail
identif
microorgan
current
easier
chang
previou
think
regard
caus
cap
inform
obtain
moder
sever
cap
patient
need
hospit
care
numer
virus
bacteria
respons
cap
infect
caus
singl
microorgan
coinfect
also
possibl
recent
studi
show
respiratori
virus
main
caus
among
bacteria
pneumonia
remain
commonli
identifi
caus
cap
repres
minor
patient
metaanalysi
also
found
respiratori
virus
particularli
influenza
respiratori
syncyti
viru
rsv
common
caus
cap
hospit
adult
coinfect
virus
bacteria
found
report
tabl
marker
infect
fever
chill
leukocytosi
respiratori
sign
andor
symptom
cough
sputum
product
short
breath
chest
pain
abnorm
pulmonari
examin
new
chang
infiltr
chest
xray
consist
cap
diagnosi
cap
challeng
specif
group
elderli
comorbid
immunosuppress
state
characterist
present
cap
present
empir
therapi
mainli
base
sever
diseas
extens
diagnost
test
standard
care
respons
agent
identifi
patient
extens
diagnost
test
seem
use
patient
present
sever
cap
result
test
may
lead
individu
therapi
diagnosi
cap
clinician
must
determin
sever
infect
decid
adequ
antibiot
use
patient
need
either
gener
ward
icu
hospit
sever
clinic
scale
sever
avail
curb
apach
ii
sofa
psi
piro
smart
cop
curb
base
five
simpl
paramet
confus
urea
respiratori
rate
blood
pressur
age
curb
stratifi
patient
accord
risk
death
lead
manag
higher
risk
requir
aggress
intervent
apach
ii
sofa
mainli
use
critic
ill
patient
scale
mention
particularli
use
cap
patient
evalu
none
includ
cytokin
level
anoth
immun
biomark
compon
scale
antibiot
select
base
mainli
epidemiolog
set
patient
sever
cap
well
known
start
earli
therapi
relat
better
prognosi
delay
h
initi
present
first
antibiot
dose
associ
increas
inhospit
mortal
window
even
shorter
h
patient
septic
shock
due
cap
length
therapi
vari
day
case
outpati
cap
without
comorbid
treat
macrolid
case
patient
coexist
ill
inpati
macrolid
plu
betalactam
must
use
monotherapi
respiratori
fluoroquinolon
levofloxacin
moxifloxacin
regimen
cure
approxim
patient
mild
moder
cap
sever
cap
requir
icu
manag
due
aggress
bacteria
pseudomona
aeruginosa
staphylococcu
aureu
recommend
cover
bacteria
specif
antibiot
must
consid
adjuv
therapi
sever
cap
includ
system
steroid
statin
immunomodulatori
agent
use
deserv
research
recommend
idsaat
guidelin
cap
among
recommend
antibiot
macrolid
may
play
role
immun
modul
prospect
studi
patient
admit
cap
show
higher
level
c
reactiv
protein
crp
procalcitonin
pct
bacteremia
compar
cap
unknown
caus
consid
secondari
bacteria
differ
cytokin
profil
biomark
found
depend
caus
atyp
bacteria
lower
pct
enterobacteriacea
higher
pneumonia
high
pct
legionella
pneumophila
higher
crp
pediatr
popul
studi
demonstr
associ
sever
lung
necrosi
cap
due
pneumonia
brazilian
popul
cap
level
show
good
associ
sever
score
apach
ii
howev
studi
support
find
level
associ
earli
death
studi
patient
patient
treatment
failur
correl
level
gene
polymorph
associ
sever
sepsi
acut
respiratori
failur
icu
hospit
mortal
egyptian
children
cap
howev
found
similar
concentr
differ
genotyp
find
may
indic
cap
suscept
multifactori
diseas
molecul
gene
may
involv
paat
et
al
report
patient
cap
show
high
level
subset
express
signatur
cytokin
interleukin
cell
bal
peripher
blood
suggest
protect
role
previous
associ
neutrophil
inflamm
product
defensin
import
clearanc
fungi
extracellular
bacteria
pneumonia
common
caus
microorgan
studi
includ
cap
patient
year
old
median
year
cap
patient
year
old
median
year
serum
concentr
proinflammatori
antiinflammatori
cytokin
receptor
antagonist
differ
age
group
although
level
admiss
tend
higher
elderli
patient
cytokin
level
posit
correl
psi
young
elderli
patient
result
suggest
elderli
patient
show
reduct
system
inflammatori
respons
admiss
cap
stromalcellderiv
chemotact
cytokin
cxc
chemokin
famili
regul
movement
neutrophil
monocyt
lymphocyt
basophil
also
induc
cell
migrat
cell
adhes
neutrophil
activ
inflamm
posit
correl
apach
ii
especi
psi
score
patient
cap
therefor
use
biolog
marker
earli
diagnosi
cap
explor
futur
studi
matrix
metalloproteinas
mmp
larg
famili
zincdepend
endopeptidas
also
anoth
import
biomark
addit
mmp
known
major
enzym
respons
proteolyt
degrad
proteinac
compon
extracellular
matrix
ecm
mmp
also
interact
multipl
cytokin
particip
patholog
infect
inflamm
mmp
key
factor
pathogenesi
variou
type
pneumonia
summari
cytokin
respons
play
import
role
clinic
evolut
sever
bacteri
cap
import
cytokin
previous
correl
wors
outcom
level
shown
good
associ
predict
score
apach
ii
high
level
associ
develop
acut
kidney
injuri
necess
invas
mechan
ventil
earli
death
mortal
anoth
biomark
posit
correl
clinic
score
pathogenesi
less
import
clinic
evolut
inflammatoryag
phenomenon
observ
older
patient
must
consid
analyz
present
data
sever
viral
cap
differ
specif
viru
also
differ
age
group
influenza
viru
iav
infect
common
caus
pneumoniarel
death
develop
world
mortal
attribut
iav
infect
much
higher
pandem
current
avail
agent
treat
iav
infect
includ
oseltamivir
zanamivir
inhibit
viral
na
therefor
effect
limit
viral
replic
earli
stage
infect
immunocompromis
patient
less
effect
antivir
innat
immun
respons
establish
presenc
viral
rna
cytosol
activ
three
major
intracellular
immun
pathway
initi
innat
immun
respons
toward
viru
retino
acid
induc
protein
tolllik
receptor
tlr
primarili
inflammasom
bind
viral
rna
helicas
domain
trigger
interact
mitochondriaassoci
antivir
signal
protein
mav
induc
gener
type
iii
interferon
activ
proinflammatori
transcript
factor
nuclear
factor
nf
replic
influenza
viru
replic
critic
depend
cellular
activ
crucial
proinflammatori
signal
modul
suggest
strategi
inhibit
pathway
may
suitabl
intervent
final
gmcsf
import
mediat
antivir
host
defens
factor
promot
repair
alveolar
epithelium
import
mediat
influenza
pneumonia
recent
studi
demonstr
associ
diseas
progress
among
hospit
patient
influenza
identifi
one
critic
mediat
damag
due
influenza
viru
also
significantli
elev
non
pneumonia
patient
patient
infect
influenza
show
strong
respons
demonstr
anim
model
develop
sever
pneumonia
experiment
infect
influenza
howev
mice
amelior
acut
lung
injuri
mice
treat
monoclon
antibodi
protect
acut
lung
injuri
research
group
report
high
level
inflammatori
cytokin
found
human
lung
tissu
fatal
case
influenza
season
find
may
indic
inflammatori
cytokin
storm
involv
immunopathogenesi
influenza
pneumonia
regulatori
mechan
enough
control
inflammatori
respons
final
immunoregulatori
cytokin
play
import
role
inflammatori
process
rendonramirez
et
al
found
neg
correl
sofa
score
level
patient
influenza
rsv
infect
common
young
children
earli
immun
respons
cytokin
import
chemokin
involv
neutrophil
recruit
produc
adapt
immun
respons
detect
patient
infect
rsv
cytokin
induc
chemokin
implic
neutrophil
recruit
effect
induct
mucu
overproduct
inhibit
cytotox
mediat
lymphocyt
children
rsvassoci
pneumonia
present
low
level
probabl
indic
poor
cell
stimul
fact
high
level
found
patient
cytokin
pattern
characterist
respons
coexist
control
infect
andor
avoid
tissu
injuri
summari
preponder
cytokin
influenza
pneumonia
relev
cytokin
influenza
viru
replic
critic
depend
cellular
activ
gmcsf
import
mediat
antivir
host
defens
factor
promot
repair
alveolar
epithelium
mediat
diseas
progress
influenza
level
exclus
influenza
must
question
individu
infect
rsv
show
high
level
cytokin
relat
lymphocyt
subpopul
littl
known
respiratori
virus
opportun
explor
specif
cytokin
pattern
sever
nonspecif
noncytokin
biomark
use
togeth
sever
pneumonia
score
crp
btype
natriuret
peptid
bnp
ddimer
ace
activ
procalcitonin
crp
day
antibiot
therapi
marker
good
prognosi
show
decreas
crp
mgl
independ
associ
lower
risk
mortal
crp
level
fail
fall
independ
associ
mortal
auroc
crp
smaller
psi
bnp
increas
independ
associ
mortal
auroc
bnp
compar
auroc
psi
ad
bnp
psi
significantli
improv
prognost
accuraci
psi
alon
ddimer
ace
activ
controversi
result
mortal
impact
procalcitonin
anoth
import
biomark
semiquantit
procalcitonin
serum
level
hospit
admiss
less
predict
mortal
cap
compar
blood
urea
nitrogenserum
albumin
ba
ratio
patient
serum
procalcitonin
level
ngml
requir
intens
care
lower
level
meanwhil
pct
kinet
first
h
use
tool
predict
mortal
patient
sever
sepsi
septic
shock
admit
intermedi
care
unit
causal
microorgan
play
key
role
host
respons
may
trigger
differ
inflammatori
respons
depend
intrins
properti
presenc
capsul
lipopolysaccharid
cell
wall
virul
factor
spread
infect
solubl
receptor
advanc
glycat
end
product
srage
solubl
form
rage
elev
inflammatori
condit
acut
lung
injuri
acut
respiratori
distress
syndrom
ard
associ
elev
srage
fatal
outcom
suggest
may
independ
causal
effect
cap
sofa
score
clinic
factor
abil
identifi
surviv
ard
patient
logist
regress
model
demonstr
sofa
srage
variabl
modifi
probabl
fatal
outcom
littl
known
regard
particip
immunoglobulin
isotyp
pathogenesi
sever
diseas
caus
viru
studi
evalu
associ
plasma
level
iga
igm
ige
outcom
patient
sever
pandem
influenza
found
high
igm
level
admiss
icu
good
prognost
factor
patient
sever
diseas
caus
influenza
find
indic
central
role
igm
prevent
uncontrol
inflammatori
respons
mortal
earli
assess
igm
could
contribut
direct
clinic
decis
patient
system
corticosteroid
antiinflammatori
effect
may
attenu
local
system
inflammatori
process
observ
cap
cap
treat
corticosteroid
experienc
greater
declin
level
crp
effect
steroid
immun
system
mani
complex
corticosteroid
switch
gene
encod
proinflammatori
cytokin
eg
switch
gene
encod
antiinflammatori
cytokin
eg
howev
use
steroid
also
exert
influenc
immun
function
differ
host
defens
bacteria
high
dosag
prolong
treatment
use
corticosteroid
studi
cap
focus
clinic
outcom
role
cytokin
metaanalysi
find
benefit
inclus
corticosteroid
treatment
cap
adult
studi
heterogen
restrict
sever
cap
multicent
random
doubleblind
placebocontrol
trial
compar
methylprednisolon
placebo
patient
sever
cap
high
inflammatori
respons
defin
creactiv
protein
level
greater
mgl
corticosteroid
reduc
risk
treatment
failur
inhospit
mortal
differ
anoth
doubleblind
random
multicent
studi
compar
day
prednison
mg
placebo
adult
patient
hospit
cap
studi
largest
avail
includ
patient
prednison
group
includ
individu
placebo
group
contain
individu
median
time
clinic
stabil
shorter
prednison
group
placebo
group
pneumoniaassoci
complic
day
differ
group
prednison
group
placebo
group
studi
conclud
prednison
given
day
patient
hospit
cap
shorten
time
clinic
stabil
without
increas
complic
inhal
corticosteroid
ic
treatment
patient
asthma
copd
cap
associ
reduc
system
inflammatori
respons
patient
receiv
ic
reduc
level
impact
longterm
mortal
current
antibiot
recommend
treatment
cap
macrolid
clarithromycin
azithromycin
seem
produc
signific
immunomodulatori
effect
effect
includ
suppress
specif
transcript
factor
result
decreas
product
proinflammatori
cytokin
decreas
neutrophil
chemotaxi
airway
increas
product
antiinflammatori
cytokin
addit
macrolid
shown
inhibit
biofilm
format
decreas
mucu
hypersecret
lead
improv
mucociliari
clearanc
spite
effect
macrolid
use
show
improv
mortal
compar
fluoroquinolon
patient
cap
larger
systemat
review
metaanalysi
evalu
macrolid
use
mortal
due
cap
studi
almost
patient
found
statist
signific
lower
risk
mortal
compar
nonmacrolid
heterogen
among
studi
substanti
howev
benefit
may
relat
nonantimicrobi
immun
modulatori
properti
macrolid
influenza
pneumonia
associ
hypercytokinemia
prospect
random
clinic
trial
enrol
patient
use
oseltamivir
azithromycin
combin
therapi
influenza
conduct
although
differ
inflammatori
cytokin
express
level
statist
signific
combin
therapi
show
earli
resolut
symptom
statin
pleiotrop
effect
impact
immunomodulatori
antiinflammatori
antithrombot
direct
microbicid
action
statin
known
downregul
cytokin
transcript
factor
abnorm
increas
sepsi
sever
vitro
vivo
studi
demonstr
statin
reduc
level
creactiv
protein
effect
inhibit
upregul
cytokin
potenti
decreas
inflamm
immun
dysfunct
consequ
statin
may
decreas
sever
symptom
associ
sepsi
metaanalysi
perform
includ
studi
reveal
associ
statin
risk
mortal
cap
howev
result
constitut
low
qualiti
evid
base
grade
framework
due
observ
studi
design
heterogen
public
bia
given
biolog
plausibl
find
high
burden
mortal
cap
metaanalysi
result
warrant
addit
betterdesign
studi
defin
util
statin
cap
recent
multicent
doubl
blind
random
clinic
trial
studi
rosuvastatin
versu
placebo
patient
sepsisassoci
acut
respiratori
distress
syndrom
case
due
pneumonia
patient
improv
clinic
outcom
rosuvastatin
may
contribut
higher
degre
hepat
renal
dysfunct
anoth
random
doubleblind
placebocontrol
trial
design
determin
simvastatin
mg
daili
day
hospit
patient
cap
improv
clinic
outcom
reduc
concentr
inflammatori
cytokin
result
suggest
statin
reduc
either
time
clinic
stabil
level
inflammatori
cytokin
linezolid
antibiot
oxazolidinon
class
uniqu
immunomodulatori
effect
murin
model
postinfluenza
commun
acquir
mrsa
pneumonia
use
associ
reduc
level
chemotact
chemokin
inflammatori
cytokin
kc
bronchoalveolar
lavag
significantli
lower
level
pantonvalentin
leukocidin
toxin
lung
linezolid
also
show
reduc
lung
injuri
compar
vancomycin
hypercytokinemia
immun
dysregul
describ
patient
sever
cap
multipl
adjuv
therapi
pneumonia
investig
none
current
licens
success
treatment
must
target
toward
immun
respons
promis
biomark
exist
yet
reach
common
bedsid
practic
corticosteroid
agent
regul
cytokin
dysregul
may
prevent
treatment
failur
improv
outcom
cap
use
steroid
sever
cap
promis
find
howev
integr
evalu
necessari
especi
case
comorbid
studi
design
defin
role
immunomodulatori
agent
coadjuv
therapi
cap
need
